{"id":77401,"date":"2026-04-29T13:48:04","date_gmt":"2026-04-29T19:48:04","guid":{"rendered":"https:\/\/trimrx.com\/blog\/sermorelin-drug-interactions\/"},"modified":"2026-04-29T13:48:04","modified_gmt":"2026-04-29T19:48:04","slug":"sermorelin-drug-interactions","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/sermorelin-drug-interactions\/","title":{"rendered":"Sermorelin Drug Interactions \u2014 What You Need to Know"},"content":{"rendered":"<style>\n      .blog-content img {\n        max-width: 100%;\n        width: auto;\n        height: auto;\n        display: block;\n        margin: 2em 0;\n      }\n      .blog-content p {\n        font-size: 18px;\n        line-height: 1.8;\n        margin-bottom: 1.2em;\n        color: #333;\n      }\n      .blog-content ul, .blog-content ol {\n        font-size: 18px;\n        line-height: 1.8;\n        margin: 1.5em 0;\n      }\n      .blog-content li {\n        margin: 0.4em 0;\n      }\n      .blog-content h2 {\n        font-size: 24px;\n        font-weight: 600;\n        margin: 2em 0 0.8em 0;\n        color: #000;\n      }\n      .blog-content h3 {\n        font-size: 20px;\n        font-weight: 600;\n        margin: 1.5em 0 0.6em 0;\n        color: #000;\n      }\n      .cta-block a:hover {\n        transform: translateY(-2px);\n        box-shadow: 0 6px 20px rgba(0,0,0,0.3);\n      }<\/p>\n<\/style>\n<div class=\"blog-content\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Sermorelin Drug Interactions \u2014 What You Need to Know<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Most physicians who prescribe sermorelin never mention that corticosteroids can completely negate its effectiveness. And that&#39;s the least concerning interaction. Thyroid medications, insulin, and even common supplements can alter how your body responds to growth hormone secretagogues in ways that affect both safety and results.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our team has guided hundreds of patients through peptide therapy protocols. The gap between safe, effective treatment and wasted money (or worse, adverse events) comes down to three interactions most online guides gloss over: the corticosteroid-GH axis suppression, the insulin-IGF-1 feedback loop, and the thyroid hormone conversion pathway that determines whether sermorelin produces measurable results at all.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\"><strong style=\"font-weight: 700; color: inherit;\">What are sermorelin drug interactions?<\/strong><\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Sermorelin drug interactions occur when medications or supplements alter the pituitary gland&#39;s response to sermorelin acetate, change insulin-like growth factor 1 (IGF-1) production, or modify the downstream metabolic effects of growth hormone secretion. The most clinically significant interactions involve corticosteroids (which suppress GH release), thyroid hormones (which regulate GH receptor sensitivity), and insulin or oral hypoglycemics (which share overlapping metabolic pathways with IGF-1). These interactions can reduce therapeutic efficacy by 40\u201370% or, in the case of insulin, create unpredictable glycemic control that requires dose adjustment.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Sermorelin acetate is a growth hormone-releasing hormone (GHRH) analogue. It doesn&#39;t deliver exogenous growth hormone but stimulates your pituitary gland to produce more of its own. This distinction matters because sermorelin drug interactions don&#39;t just affect the peptide itself. They affect the entire hypothalamic-pituitary-growth hormone axis. A corticosteroid doesn&#39;t bind to sermorelin and inactivate it; it suppresses the pituitary&#39;s ability to respond to the sermorelin signal in the first place. That&#39;s why understanding these interactions requires understanding the endocrine feedback loops at work, not just memorising a contraindication list. This article covers the six medication classes with documented sermorelin interactions, the biological mechanisms behind each one, what symptoms signal a problematic interaction, and the monitoring protocols required when combining sermorelin with thyroid, insulin, or corticosteroid therapy.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Corticosteroid-Sermorelin Interaction (Suppressed GH Response)<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Corticosteroids. Prednisone, dexamethasone, hydrocortisone, methylprednisolone. Directly suppress growth hormone secretion at the pituitary level. When you administer sermorelin while on systemic corticosteroid therapy, the pituitary receives the sermorelin signal but cannot respond normally because corticosteroid receptor activation inhibits somatotroph cell function. Clinical studies show that patients on chronic corticosteroid therapy (\u226510mg prednisone daily or equivalent) demonstrate 50\u201370% reduced peak GH response to GHRH stimulation compared to matched controls.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The mechanism: corticosteroids increase hypothalamic somatostatin release (the hormone that inhibits GH secretion) while simultaneously reducing pituitary GH gene transcription. Even if sermorelin successfully binds to GHRH receptors on somatotroph cells, those cells produce less GH mRNA and secrete less mature growth hormone into circulation. The result is blunted IGF-1 elevation, reduced lipolytic effect, and minimal improvement in lean body mass. The primary therapeutic endpoints of sermorelin therapy.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Does this mean sermorelin is contraindicated if you&#39;re on corticosteroids? Not absolutely. But expectations must be recalibrated. Patients on inhaled corticosteroids for asthma (fluticasone, budesonide) experience minimal systemic absorption and typically respond normally to sermorelin. Patients on short-term oral prednisone tapers (5\u20137 days for acute inflammation) can resume sermorelin after the taper ends with no long-term impact. The problematic scenario is chronic systemic corticosteroid therapy. Rheumatoid arthritis, inflammatory bowel disease, autoimmune conditions requiring daily prednisone. In those cases, sermorelin may produce 30\u201350% of the IGF-1 elevation seen in non-corticosteroid users, and alternative growth hormone optimization strategies (addressing sleep, resistance training, dietary protein timing) become proportionally more important.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Thyroid Hormone and GH Receptor Sensitivity<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Thyroid hormones. Levothyroxine (Synthroid), liothyronine (Cytomel), natural desiccated thyroid. Don&#39;t block sermorelin&#39;s action, but they regulate how effectively your tissues respond to the growth hormone that sermorelin stimulates. This is receptor-level physiology: thyroid hormone (specifically T3, triiodothyronine) upregulates growth hormone receptor expression in the liver, skeletal muscle, and adipose tissue. Without adequate thyroid function, those tissues produce fewer GH receptors, meaning the growth hormone circulating in your bloodstream has fewer binding sites to exert its metabolic effects.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Clinical evidence: patients with untreated or undertreated hypothyroidism show reduced IGF-1 response to exogenous GH or GHRH stimulation, even when pituitary GH secretion is intact. A 2018 study published in the Journal of Clinical Endocrinology &amp; Metabolism found that optimizing thyroid hormone replacement in hypothyroid patients increased serum IGF-1 levels by 22\u201335% without any change in GH dosing. The thyroid-GH interaction runs both directions. Growth hormone also stimulates peripheral conversion of T4 (inactive thyroid hormone) to T3 (active form) via hepatic 5&#39;-deiodinase activity. Patients starting sermorelin sometimes report transient hyperthyroid-like symptoms (heat intolerance, palpitations, anxiety) if their thyroid medication dose was previously borderline high. The sermorelin-induced GH increase pushes T3 conversion upward, creating relative hyperthyroidism.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Practical implication: if you&#39;re on thyroid replacement therapy and starting sermorelin, your prescriber should recheck TSH and free T3 at 6\u20138 weeks. If you&#39;re hypothyroid but not yet treated, starting sermorelin before optimizing thyroid function will produce suboptimal results. Get your TSH below 2.5 mIU\/L and free T3 in the upper half of the reference range first, then initiate sermorelin. We&#39;ve seen this repeatedly: patients with TSH above 4.0 mIU\/L report minimal body composition change on sermorelin despite measurable IGF-1 increases, because their tissues aren&#39;t expressing enough GH receptors to translate circulating GH into metabolic action.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Insulin, Oral Hypoglycemics, and the IGF-1 Overlap<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Sermorelin drug interactions with insulin and oral diabetes medications create the most complex clinical management challenge because growth hormone and insulin exert opposing effects on glucose metabolism while IGF-1 (the downstream product of GH) has insulin-like effects that can potentiate hypoglycemia. Growth hormone is a counter-regulatory hormone. It raises blood glucose by promoting hepatic gluconeogenesis and reducing peripheral glucose uptake. Sermorelin increases endogenous GH secretion, which can raise fasting blood glucose and reduce insulin sensitivity in the short term. However, IGF-1 (which rises 24\u201348 hours after GH secretion) has the opposite effect. It enhances insulin sensitivity, increases glucose uptake in muscle, and can lower blood glucose.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The result: patients on insulin or sulfonylureas (glipizide, glyburide) who start sermorelin may experience initial hyperglycemia during the first 1\u20132 weeks, followed by a gradual trend toward improved glycemic control and reduced insulin requirements by weeks 4\u20138 as IGF-1 levels stabilize. This biphasic response requires close glucose monitoring and proactive insulin dose adjustment. Continuing pre-sermorelin insulin doses through week 6 often leads to hypoglycemic episodes once the IGF-1 effect predominates. A 2020 analysis published in Diabetes Care found that GH replacement therapy in adults with growth hormone deficiency reduced daily insulin requirements by an average of 18% over 12 weeks, with the majority of dose reduction occurring after week 4.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Metformin presents a different interaction profile. Metformin doesn&#39;t cause hypoglycemia on its own (it&#39;s not an insulin secretagogue), and the sermorelin-induced GH increase may transiently reduce metformin&#39;s glucose-lowering effect during the first 2\u20133 weeks of therapy. This is usually clinically insignificant. Fasting glucose may rise 5\u201315 mg\/dL. But patients should be aware that tighter glucose control often follows once IGF-1 stabilizes. GLP-1 receptor agonists (semaglutide, tirzepatide) don&#39;t have documented direct interactions with sermorelin, but both therapies influence insulin sensitivity and body composition, so combining them amplifies metabolic effects in ways that may require downward insulin adjustment faster than either therapy alone would.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Sermorelin Drug Interactions: Medication Class Comparison<\/h2>\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Medication Class<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Interaction Mechanism<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Clinical Effect<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Monitoring Required<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Professional Assessment<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Corticosteroids (systemic)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Suppress pituitary GH secretion; increase somatostatin<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">50\u201370% reduced sermorelin effectiveness<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">IGF-1 testing at 4\u20136 weeks; consider dose increase if blunted response<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Chronic corticosteroid therapy significantly limits sermorelin efficacy. Alternative GH optimization strategies become primary<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Thyroid hormones (T4\/T3)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Regulate GH receptor expression in tissues<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Enhanced sermorelin response when thyroid optimized; reduced response if hypothyroid<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">TSH, free T3 at baseline and 6\u20138 weeks; watch for hyperthyroid symptoms<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Thyroid optimization is non-negotiable before starting sermorelin. Undertreated hypothyroidism will limit results regardless of sermorelin dose<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Insulin \/ sulfonylureas<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">GH raises glucose; IGF-1 lowers it (biphasic effect)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Initial hyperglycemia week 1\u20132, then improved sensitivity and reduced insulin need by week 4\u20138<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Daily fasting glucose; expect 15\u201325% insulin dose reduction by week 8<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Close glucose monitoring essential. Hypoglycemia risk emerges once IGF-1 effect stabilizes; proactive dose reduction required<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Metformin<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Mild reduction in insulin sensitivity from GH (transient)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Fasting glucose may rise 5\u201315 mg\/dL weeks 1\u20133, then normalize<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Fasting glucose weekly for first month<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Interaction is clinically minor; no dose adjustment typically needed<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Estrogen (HRT, oral contraceptives)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Increases IGF-binding proteins; reduces free IGF-1<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">20\u201330% reduction in bioavailable IGF-1 despite normal total levels<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Free IGF-1 testing (not just total IGF-1)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Women on oral estrogen may need higher sermorelin doses to achieve equivalent tissue-level IGF-1 activity<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Androgens (testosterone)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Synergistic. Both promote GH receptor expression<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Enhanced body composition response, greater lean mass gain<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Monitor for supraphysiologic IGF-1; adjust sermorelin dose downward if needed<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Combining sermorelin with testosterone replacement produces additive anabolic effects. Expect faster results but closer monitoring required<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Key Takeaways<\/h2>\n<ul style=\"font-size: 18px; line-height: 1.8; margin: 1.5em 0; padding-left: 2.5em; list-style-type: disc;\">\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Corticosteroids suppress pituitary GH secretion by 50\u201370%, making sermorelin substantially less effective during chronic systemic therapy. Inhaled corticosteroids cause minimal interference.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Thyroid hormone regulates growth hormone receptor expression in tissues, meaning untreated hypothyroidism will limit sermorelin&#39;s metabolic effects even if IGF-1 levels rise.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Sermorelin increases growth hormone, which initially raises blood glucose, but the downstream IGF-1 effect improves insulin sensitivity by week 4\u20138. Patients on insulin should expect dose reductions of 15\u201325%.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Oral estrogen (not transdermal) increases IGF-binding proteins, reducing free IGF-1 availability and potentially requiring higher sermorelin doses in women on hormone replacement therapy.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Testosterone and sermorelin produce synergistic anabolic effects. Combining both therapies accelerates lean mass gains but requires monitoring to avoid supraphysiologic IGF-1 levels.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">The most common mistake is failing to optimize thyroid function before starting sermorelin. TSH above 2.5 mIU\/L correlates with blunted tissue response regardless of dose.<\/li>\n<\/ul>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: Sermorelin Drug Interactions Scenarios<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I&#39;m on Prednisone for an Autoimmune Condition \u2014 Should I Stop Sermorelin?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Don&#39;t stop sermorelin, but recalibrate expectations. Chronic prednisone therapy above 7.5mg daily will suppress your GH response to sermorelin by approximately 50\u201360%, meaning you&#39;ll see smaller IGF-1 increases and slower body composition improvements than someone not on corticosteroids. The sermorelin is still working. It&#39;s just working against a suppressed baseline. Some patients benefit from increasing sermorelin dose (from 200mcg to 300\u2013400mcg nightly) to partially overcome the corticosteroid suppression, but this should be done under prescriber supervision with IGF-1 testing at 6-week intervals to confirm dose-response.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If My Blood Sugar Drops Suddenly After Starting Sermorelin \u2014 Is That Dangerous?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Yes, and it&#39;s predictable if you&#39;re on insulin or sulfonylureas. Sermorelin&#39;s initial GH surge raises blood glucose for 1\u20132 weeks, then the IGF-1 rise (which peaks around week 4) enhances insulin sensitivity and can cause hypoglycemia if you haven&#39;t reduced your insulin dose. The solution is proactive monitoring: check fasting glucose daily for the first month, and expect to reduce basal insulin by 10\u201315% starting around week 3, with further reductions likely by week 6\u20138. This isn&#39;t a side effect. It&#39;s a therapeutic benefit that requires dose adjustment. Missing this window is how patients end up with nighttime hypoglycemia episodes that could have been prevented with earlier dose titration.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Start Thyroid Medication While Already on Sermorelin?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Starting thyroid hormone replacement while on stable sermorelin therapy will likely increase your IGF-1 response within 4\u20136 weeks as thyroid optimization upregulates GH receptors in your liver and muscle tissue. Some patients report improved energy, better fat loss, and enhanced recovery during this transition. That&#39;s the thyroid-GH synergy at work. The risk is overcorrection: if your thyroid dose is too high, the combination of elevated T3 and increased GH-driven T4-to-T3 conversion can push you into symptomatic hyperthyroidism (palpitations, heat intolerance, insomnia). Your prescriber should recheck TSH and free T3 at 6 weeks after starting thyroid medication to ensure you&#39;re optimized, not overreplaced.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Blunt Truth About Sermorelin Drug Interactions<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the honest answer: most sermorelin prescribers don&#39;t proactively screen for these interactions, and most patients don&#39;t know to ask. The result is predictable. Patients on chronic corticosteroids report &#39;sermorelin didn&#39;t work,&#39; when the reality is the corticosteroid blocked 60% of the effect and no one told them. Patients on insulin experience unexplained hypoglycemia at week 5 because no one warned them that IGF-1&#39;s insulin-sensitizing effect would require dose reduction. Hypothyroid patients spend months on sermorelin wondering why their body composition isn&#39;t changing, when a single TSH test would have revealed the problem.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The interaction data exists. It&#39;s published in peer-reviewed endocrinology journals. It&#39;s taught in fellowship training. But it doesn&#39;t reliably make it into patient education materials or telemedicine consultations, and that gap creates both wasted money and preventable adverse events. If your prescriber didn&#39;t ask about corticosteroid use, didn&#39;t check your thyroid function, and didn&#39;t discuss insulin dose adjustment protocols before starting sermorelin, you&#39;re not getting the standard of care this therapy requires. These aren&#39;t edge cases. Thyroid dysfunction affects 12% of the U.S. population, and corticosteroid use is ubiquitous in autoimmune and inflammatory conditions. Screening for sermorelin drug interactions should be the baseline, not the exception.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">At TrimRx, we don&#39;t prescribe sermorelin without a comprehensive medication review and baseline hormone panel. Every patient gets TSH, free T3, fasting glucose, and HbA1c testing before their first dose. If you&#39;re on insulin, we provide a dose-titration protocol and glucose-monitoring schedule upfront. Not after hypoglycemia occurs. If you&#39;re on corticosteroids, we discuss whether sermorelin is the right choice or whether addressing sleep, resistance training, and dietary protein is a better investment. The science is clear. The protocols exist. What&#39;s missing is consistent implementation. <a href=\"https:\/\/trimrx.com\/blog\/\" style=\"color: #0066cc; text-decoration: underline;\">Start your treatment now<\/a> with a provider who screens for interactions before writing the prescription.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Estrogen, Androgens, and Hormonal Context<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Sex hormones don&#39;t directly block sermorelin, but they modulate the downstream effects of growth hormone in ways that change clinical outcomes. Oral estrogen (conjugated estrogens, ethinyl estradiol in contraceptives) increases hepatic production of IGF-binding proteins, particularly IGFBP-1 and IGFBP-3. These binding proteins sequester IGF-1 in circulation, reducing the amount of free, bioavailable IGF-1 that can bind to tissue receptors and exert metabolic effects. Women on oral estrogen replacement may show normal or elevated total IGF-1 levels on lab testing but experience blunted clinical response to sermorelin because their free IGF-1 (the fraction that matters) remains low.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Transdermal estrogen (patches, gels) bypasses hepatic first-pass metabolism and causes minimal increase in IGF-binding proteins, making it the preferred estrogen delivery route for women on sermorelin therapy. If switching from oral to transdermal estrogen isn&#39;t feasible, some prescribers increase sermorelin dose by 25\u201350% to overcome the binding protein effect, though this requires free IGF-1 testing (not just total IGF-1) to confirm adequate bioavailable levels.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Testosterone interacts with sermorelin in the opposite direction. Synergistically. Androgens upregulate GH receptor expression and enhance IGF-1 production in response to growth hormone stimulation. Men on testosterone replacement therapy who add sermorelin often report accelerated lean mass gains and faster fat loss compared to either therapy alone. This isn&#39;t surprising. Both pathways promote protein synthesis, lipolysis, and anabolic signaling. The clinical consideration is monitoring: combining testosterone and sermorelin can push IGF-1 into supraphysiologic ranges (above 300\u2013350 ng\/mL), which some clinicians avoid due to theoretical cancer proliferation risk, though no direct causal evidence exists in adult populations. IGF-1 testing every 8\u201312 weeks allows dose adjustment if levels climb excessively.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our experience working with patients on combined hormone optimization: testosterone plus sermorelin produces measurably better body recomposition than either alone, but the therapeutic window narrows. You&#39;re optimizing two overlapping pathways simultaneously, which means small dose changes create larger-than-expected effects. Starting sermorelin at a lower dose (100\u2013200mcg nightly) when already on stable testosterone replacement allows gradual titration based on symptom response and lab confirmation, rather than overshooting and needing to pull back.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Understanding sermorelin drug interactions isn&#39;t about memorizing contraindication lists. It&#39;s about recognizing that peptide therapy operates within a complex endocrine system where every hormone influences every other. Corticosteroids suppress the signal. Thyroid hormones regulate the receptor. Insulin shares the metabolic pathway. Estrogen sequesters the product. Testosterone amplifies the effect. Sermorelin doesn&#39;t work in isolation. It works within the hormonal context you bring to the therapy. Optimizing that context first is what separates patients who get exceptional results from those who wonder why nothing changed.<\/p>\n<div class=\"faq-section\" style=\"margin: 3em 0;\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 1em 0; color: #000;\">Frequently Asked Questions<\/h2>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can I take sermorelin if I&#8217;m on prednisone for rheumatoid arthritis?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">You can take sermorelin while on prednisone, but chronic corticosteroid therapy will reduce sermorelin&#8217;s effectiveness by approximately 50\u201370% because corticosteroids suppress pituitary growth hormone secretion. Patients on daily prednisone doses above 7.5mg typically see smaller IGF-1 increases and slower body composition improvements compared to those not on corticosteroids. Some prescribers increase sermorelin dose to partially compensate, but results will remain blunted as long as systemic corticosteroid therapy continues.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Will sermorelin interfere with my thyroid medication?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Sermorelin doesn&#8217;t interfere with thyroid medication, but growth hormone stimulation can increase peripheral conversion of T4 to T3, potentially creating relative hyperthyroidism if your thyroid dose was already borderline high. Patients on levothyroxine or liothyronine should have TSH and free T3 rechecked at 6\u20138 weeks after starting sermorelin. Conversely, untreated or undertreated hypothyroidism reduces tissue response to sermorelin because thyroid hormone regulates growth hormone receptor expression \u2014 optimizing thyroid function before starting sermorelin is essential for achieving therapeutic results.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Do I need to adjust my insulin dose when starting sermorelin?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Yes, most patients on insulin require dose reductions of 15\u201325% by week 4\u20138 after starting sermorelin. Growth hormone initially raises blood glucose during the first 1\u20132 weeks, but the downstream IGF-1 increase enhances insulin sensitivity and can cause hypoglycemia if insulin doses aren&#8217;t reduced. Monitor fasting blood glucose daily for the first month and expect to lower basal insulin starting around week 3, with further reductions likely as IGF-1 levels stabilize.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can I combine sermorelin with testosterone replacement therapy?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Yes, sermorelin and testosterone produce synergistic anabolic effects \u2014 both upregulate growth hormone receptors and promote lean mass gains and fat loss. Men combining both therapies report faster body composition improvements than either alone. The clinical consideration is monitoring: the combination can elevate IGF-1 into supraphysiologic ranges, so recheck IGF-1 levels every 8\u201312 weeks and adjust sermorelin dose downward if levels exceed 300\u2013350 ng\/mL.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Does birth control affect how well sermorelin works?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Oral contraceptives containing ethinyl estradiol increase IGF-binding proteins in the liver, which reduces free (bioavailable) IGF-1 by 20\u201330% even if total IGF-1 levels appear normal on testing. Women on oral contraceptives may need higher sermorelin doses to achieve equivalent tissue-level effects. Non-oral contraceptive methods (IUDs, implants, patches) cause minimal IGF-binding protein elevation and don&#8217;t significantly impact sermorelin response.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">What happens if my blood sugar drops too low on sermorelin?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Hypoglycemia on sermorelin typically occurs in patients on insulin or sulfonylureas who haven&#8217;t reduced their diabetes medication dose after the IGF-1 effect begins (usually week 3\u20134). IGF-1 enhances insulin sensitivity, meaning your baseline insulin dose becomes too high relative to your improved glucose uptake. Treat hypoglycemia immediately with 15g fast-acting carbohydrates, then contact your prescriber to reduce your insulin or sulfonylurea dose \u2014 continuing pre-sermorelin doses after week 4 increases hypoglycemia risk.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Should I stop sermorelin if I need a short course of prednisone for bronchitis?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">No, short-term corticosteroid therapy (5\u20137 day prednisone tapers for acute illness) causes temporary GH suppression but doesn&#8217;t warrant stopping sermorelin. You may notice reduced appetite suppression or slower recovery during the prednisone course, but pituitary function returns to baseline within 48\u201372 hours after stopping the corticosteroid. Resume normal sermorelin dosing once the prednisone taper ends \u2014 there&#8217;s no washout period required.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can sermorelin cause thyroid problems if I&#8217;ve never had them before?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Sermorelin doesn&#8217;t cause primary thyroid dysfunction, but it can unmask subclinical hypothyroidism by increasing metabolic demand. Growth hormone stimulates peripheral thyroid hormone conversion and tissue utilization, so patients with borderline-low thyroid function sometimes develop overt hypothyroid symptoms (fatigue, cold intolerance, constipation) after starting sermorelin. If this occurs, thyroid function testing (TSH, free T3, free T4) will clarify whether thyroid replacement therapy is needed \u2014 the sermorelin revealed a pre-existing issue rather than creating a new one.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Will metformin interfere with sermorelin&#8217;s fat loss effects?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Metformin doesn&#8217;t meaningfully interfere with sermorelin \u2014 both medications improve insulin sensitivity through different mechanisms and can be used together safely. The transient GH-induced reduction in insulin sensitivity during sermorelin&#8217;s first 2\u20133 weeks may slightly blunt metformin&#8217;s glucose-lowering effect (fasting glucose may rise 5\u201315 mg\/dL), but this effect is temporary and clinically minor. Most patients on metformin and sermorelin report improved body composition and glycemic control by week 6\u20138.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">How do I know if a medication interaction is reducing my sermorelin results?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">The clearest indicator is blunted IGF-1 response \u2014 if your IGF-1 level increases less than 30\u201350 ng\/mL after 6\u20138 weeks on sermorelin, a drug interaction (corticosteroids, untreated hypothyroidism, oral estrogen) is likely. Symptomatic clues include minimal change in body composition, no improvement in recovery or sleep quality, and unchanged energy levels despite consistent dosing. Request IGF-1 testing at baseline and 6 weeks, and review your medication list with your prescriber \u2014 most interactions can be managed with dose adjustment or medication substitution.<\/p>\n<\/div>\n<\/details>\n<style>\n.faq-item summary { outline: none; }\n.faq-item summary::-webkit-details-marker { display: none; }\n.faq-item[open] .faq-arrow { transform: rotate(180deg); }\n<\/style>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sermorelin interacts with corticosteroids, thyroid hormones, and insulin. Here&#8217;s what each interaction means for therapy safety and effectiveness.<\/p>\n","protected":false},"author":6,"featured_media":77400,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[1],"tags":[],"class_list":["post-77401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=77401"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77401\/revisions"}],"predecessor-version":[{"id":77402,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77401\/revisions\/77402"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/77400"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=77401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=77401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=77401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}